3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
2
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
3
Ovarian Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
pembrolizumab
15
Paclitaxel
15
Carboplatin
13
Specimen Handling
6
Biopsy
6
durvalumab
5
Magnetic Resonance Spectroscopy
5
dostarlimab
4
Taxes
4
Surveys and Questionnaires
4
Observation
4
Letrozole
4
Everolimus
4
Cisplatin
4
olaparib
3
lenvatinib
3
ceralasertib
3
Doxorubicin
3
sacituzumab govitecan
2
pertuzumab
2
copanlisib
2
cabozantinib
2
atezolizumab
2
abemaciclib
2
Trastuzumab
2
Robotic Surgical Procedures
2
Pemetrexed
2
Nivolumab
2
Metformin
2
Megestrol Acetate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Endometrial Neoplasms
×
AZD5305
×
Clear all
NCT04644068
2026-02-19
PETRA
AstraZeneca
Phase 1/2
Active not recruiting
702 enrolled